Entrada Therapeutics (TRDA) Return on Sales (2023 - 2026)

Entrada Therapeutics' Return on Sales history runs 4 years deep, the most recent figure standing at 0.45% for Q1 2026.

• In Q1 2026, Return on Sales fell 45.0% year-over-year to 0.45%; the TTM figure through Mar 2026 stood at 0.29% (down 29.0% YoY), while the FY2025 annual figure was 0.06%, down 6.0% from the prior year.
• Return on Sales was 0.45% for Q1 2026 at Entrada Therapeutics, down from 0.3% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q3 2023 to a low of 0.45% in Q1 2026.
• Historically, Return on Sales has averaged 0.1% across 4 years, with a median of 0.01% in 2024.
• The sharpest annual moves came in 2024 and 2026: Return on Sales gained 2 bps in 2024, then sank 45 bps in 2026.
• A 4-year view of Return on Sales shows it stood at 0.0% in 2023, then jumped by 113 bps to 0.0% in 2024, then slumped by 106457 bps to 0.3% in 2025, then sank by 50 bps to 0.45% in 2026.
• The last three Return on Sales figures came in at 0.45% (Q1 2026), 0.3% (Q4 2025), and 0.27% (Q3 2025), per Business Quant data.